Geyer Felipe C, Marchio Caterina, Reis-Filho Jorge S
The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
Pathology. 2009 Jan;41(1):77-88. doi: 10.1080/00313020802563536.
Breast cancer is a heterogeneous disease, encompassing a wide variety of histological types and clinical behaviours. Current histopathological classification systems for breast cancer are based on descriptive entities that are of prognostic significance. Few predictive biomarkers are currently available. High throughput molecular technologies are reshaping our understanding of breast cancer and a molecular taxonomy that has stronger predictive power is slowly emerging. Novel therapeutic targets and prognostic/predictive gene signatures have been identified. This review will address the contribution of molecular methods to our understanding of breast cancer and its precursors, their use in breast cancer translational research and their impact on diagnostic breast cancer histopathology.
乳腺癌是一种异质性疾病,涵盖多种组织学类型和临床行为。目前的乳腺癌组织病理学分类系统基于具有预后意义的描述性实体。目前可用的预测生物标志物很少。高通量分子技术正在重塑我们对乳腺癌的理解,一种具有更强预测能力的分子分类法正在慢慢出现。已经确定了新的治疗靶点和预后/预测基因特征。本综述将阐述分子方法对我们理解乳腺癌及其前驱病变的贡献、它们在乳腺癌转化研究中的应用以及它们对乳腺癌诊断组织病理学的影响。